Journal of affective disorders

How GLP-1 single-acting drugs affect brain network communication and their potential use in mental health

Updated

Abstract

GLP-1 and GLP-1 receptor agonists (GLP-1RAs) are associated with changes in functional connectivity across multiple brain networks.

  • GLP-1 and GLP-1RAs modulate functional connectivity within the dorsal default mode network, visuospatial network, right frontal parietal network, and the salience network.
  • GLP-1 agonism is associated with decreased functional connectivity in the hypothalamus, lateral orbitofrontal cortex, and amygdala.
  • Some GLP-1RAs, such as exenatide, increase functional connectivity in the hypothalamus, nucleus tractus solitarius, and thalamus.
  • Liraglutide is associated with increased functional connectivity within the hippocampus in healthy individuals.
  • The observed changes in functional connectivity may relate to the phenomenology of various mental disorders.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Declaration of competing interest Kayla M. Teopiz has received fees from Braxia Scientific Corp. Dr. Taeho Greg Rhee was supported in part by the National Institute on Aging (#R21AG070666; R21AG078972; R01AG088647), National Institute of Mental Health (#R01MH131528), and National Institute on Drug Abuse (#R21DA057540). Dr. Rhee serves as a review committee member for Patient-Centered Outcomes Research Institute (PCORI) and Substance Abuse and Mental Health Services Administration (SAMHSA) and has received honoraria payments from PCORI and SAMHSA. Dr. Rhee has also served as a stakeholder/consultant for PCORI and received consulting fees from PCORI. Dr. Rhee serves as an advisory committee member for International Alliance of Mental Health Research Funders (IAMHRF). Dr. Joshua D Rosenblat has received research grant support from the Canadian Institute of Health Research (CIHR), Physician Services Inc. (PSI) Foundation, Labatt Brain Health Network, Brain and Cognition Discovery Foundation (BCDF), Canadian Cancer Society, Canadian Psychiatric Association, Academic Scholars Award, American Psychiatric Association, American Society of Psychopharmacology, University of Toronto, University Health Network Centre for Mental Health, Joseph M. West Family Memorial Fund and Timeposters Fellowship and industry funding for speaker/consultation/research fees from iGan, Boehringer Ingelheim, Janssen, Allergan, Lundbeck, Sunovion and COMPASS. He is the Chief Medical and Scientific Officer of Braxia Scientific and the medical director of the Canadian Rapid Treatment Centre of Excellence (Braxia Health). Dr. Roger Ho received funding from the National University of Singapore iHealthtech Other Operating Expenses (A-0001415-09-00). Dr. Roger S. McIntyre has received research grant support from CIHR/GACD/National Natural Science Foundation of China (NSFC) and the Milken Institute; speaker/consultation fees from Lundbeck, Janssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Viatris, Abbvie, Atai Life Sciences. Dr. Roger McIntyre is a CEO of Braxia Scientific Corp. Hezekiah C.T. Au, Yang Jing Zheng, Gia Han Le, Sabrina Wong, Lee Phan, and Angela T.H. Kwan have no conflicts of interests to declare.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free